UNCY - Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

PR Newswire

LOS ALTOS, Calif. , Jan. 10, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta , M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022 .

The webcast will be accessible on the Unicycive website in the Investors section under Events and Presentations on Monday, January 10, 2022, at 7:00 a.m. ET .

About Unicycive

Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com

Contacts:

ir@unicycive.com
(650) 900-5470

SOURCE Unicycive Therapeutics Inc.